Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03383094 · ClinicalTrials.gov registry record · Phase 2

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

A Phase 2 study of Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Loren Mell, MD.

Active
Registry status
Phase 2
Development phase
126
Enrollment target
6
Study locations

NCT03383094 is a Phase 2 study of Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Loren Mell, MD. The registered enrollment target is 126 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03383094, a Phase 2 study of Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Loren Mell, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
126 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).

Conditions Studied

Cancer Head and Neck Squamous Cell Carcinoma Tumor Oral Cancer Cancer Metastatic Cancer of Head and Neck Cancer, Advanced Tumor Recurrence Tumor Neck Tumor Metastasis

Interventions

  • DRUG Pembrolizumab
  • DRUG Cisplatin
  • RADIATION Radiation therapy

Study Locations (6)

Arizona

  • University of Arizona Cancer Center - Tucson

California

  • UC San Diego Moores Cancer Center - La Jolla

Florida

  • H. Lee Moffitt Cancer Center & Research Facility - Tampa

Missouri

  • Washington University School of Medicine, Siteman Cancer Center - St Louis

Ohio

  • University of Cincinnati Medical Center - Cincinnati

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2018-03-15
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

Loren Mell, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03383094

The ClinicalTrials.gov registry entry for NCT03383094 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Loren Mell, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT03383094 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, California, Florida.

Frequently Asked Questions

What is clinical trial NCT03383094 about?

NCT03383094 is a clinical study titled "Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer". The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).

What is the current status of trial NCT03383094?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2018-03-15. Estimated completion is 2027-12-31.

What conditions does trial NCT03383094 study?

This clinical trial studies the following conditions: Cancer, Head and Neck Squamous Cell Carcinoma, Tumor, Oral Cancer, Cancer Metastatic.

What interventions are being tested in trial NCT03383094?

The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Radiation therapy (RADIATION).

Who is sponsoring clinical trial NCT03383094?

This trial is sponsored by Loren Mell, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03383094 being conducted?

This trial has 6 study locations across Arizona, California, Florida, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.